Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
Part of paid clinical trials in Winston-Salem, North Carolina.
- Sponsor
- Wake Forest University Health Sciences
- Study ID
- NCT07362875
- Status
- Recruiting
Conditions
- Myotonic Dystrophy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Accepted
Study Details
Myotonic dystrophy (dystrophia myotonica; DM), the most prevalent form of muscular dystrophy in adults, is characterized by progressive myopathy, myotonia, and multi-systemic involvement. DM causes severe disability and profoundly affects the patient's quality of life. Currently, no effective treatments are available that alter the course of the disease, but ongoing clinical trials are underway.
Key Dates
- Start date
- May 15, 2025
- Status verified
- Jan 2026
- Primary completion
- May 31, 2029
- Completion
- May 31, 2029
Study Design
- Enrollment
- 75 participants (estimated)
Arms
- Arm: DM subjects1. Age 18 - 65 years 2. Diagnosis of DM1 or DM2 by clinical or genetic criteria. If DM1 or DM2 was diagnosed by clinical criteria, a first-degree relative must have genetic testing confirmation and sign a genetic consent form to release their genetic information. 3. Clinically affected, as defined by muscle weakness or myotonia 4. Ambulate independently (a walker is not permitted) 5. Able to provide informed consent for participation in the study
- Arm: Control subjects1. Age 18 - 65 years old 2. Healthy as defined by no significant medical or neurological conditions 3. Able to provide informed consent for participation in the study
Primary Outcome Measure
Contractile muscle volume (CMV, cm3) [ Time Frame: Baseline ]
Central Contacts
- Elizabeth (Gracie) G Hilber336-716-4163
- Constance Linville704-355-2000
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 |
Find similar trials in Winston-Salem, NC
By research site
Related Studies
- Biomarker Development for Muscular DystrophiesRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- Global Open-Label Extension Study of Del-desiran for the Treatment of DM1PHASE3 · Enrolling By Invitation · Avidity Biosciences, Inc. · Los Angeles, California
- Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1PHASE3 · Recruiting · Dyne Therapeutics · Atlanta, Georgia
- Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy RegistryRecruiting · University of Rochester · Rochester, New York